GCA-016 · formulation research and preclinical characterisation · Platform science
VAGINAL FORMULATIONS
We are investigating an Africa-led, lignin-based gel platform intended to support the vaginal milieu and enable future delivery of multiple active pharmaceutical compounds.
Programme:
Vaginal Formulations
Focus:
Platform science
Current stage:
Grant-funded research
Status:
GCA-016 · formulation research and preclinical characterisation
What goes inside a woman’s body should be designed to work with it.
A vaginal formulation is not only a vehicle for medicine. It enters a living environment. Our first question is whether the base respects the tissue, mucus, pH and protective bacteria—before asking what medicine it can carry.

A respectful base for more than one future medicine.
We are investigating an Africa-led, lignin-based gel platform intended to support the vaginal milieu and enable future delivery of multiple active pharmaceutical compounds.
For formulation scientists, preclinical researchers, manufacturers and clinical collaborators.
What progress could unlock.
These are the outcomes guiding development. Product claims will follow the evidence generated at the appropriate stage.
Advance locally led formulation capability
Design affordability, comfort and biological fit into the platform
Create an adaptable base for future vaginal products
Emotion opens the door. Evidence keeps us honest.
These sources support the clinical category or scientific rationale. They do not establish product-specific safety, efficacy or regulatory approval for Vaginal Formulations.
Where Vaginal Formulations stands today.
Current stage: Grant-funded research
Formulation optimisation and preclinical characterisation

